Reduction of experimentally produced acute myocardial infarction size by a new synthetic inhibitor, NCO-700, against calcium-activated neutral protease.

Publisher Website
Google Scholar
Abstract
Ca-activated neutral protease (CANP) might be involved in the irreversible degradation of myocardial proteins in the ischemic region, leading to the loss of contractility. The new compound, NCO-700, and its analogs were synthetized against CANP. Among these analogs, NCO-700 was the most potent in reducing the size of acute myocardial infarction, produced by coronary artery ligation in rabbits in vivo, although it showed less powerful action in inhibiting CANP activity in vitro. The new reagent, NCO-700, might be promising in reducing acute myocardial infarction size and beneficial for the clinical studies, because it had no action to reduce cardiac muscle contractility, compared with .beta.-antagonist or Ca-channel blockades.

This publication has 9 references indexed in Scilit: